ArticleBlood neoplasia2026
Outcomes of transplant-eligible and transplant-ineligible patients with mantle cell lymphoma in Ontario.
Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- First-Line Bruton's Tyrosine Kinase Inhibitor-Based Regimens for Mantle Cell Lymphoma.Current oncology (Toronto, Ont.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The frontline treatment of patients with mantle cell lymphoma (MCL) varies in practice. We conducted a retrospective, population-based study of patients with MCL from 2005 to 2020. We defined transplant-eligible (TE) patients as those aged <70 years who received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or R-CHOP/R-DHAP (rituximab, dexamethasone, high-dose cytarabine and dexamethasone) and transplant-ineligible (TI) patients as those aged ≥70 years and treated with bendamustine-rituximab (BR) or other chemoimmunotherapy regimens. The primary outcome was 5-year overall survival (OS), and secondary outcomes included toxicities and health care use. We identified 426 TE patients, of whom 254 received R-CHOP and 172 received R-CHOP/R-DHAP. More patients who received R-CHOP/R-DHAP also received an autologous stem cell transplant (ASCT). The 5-year OS for patients treated with R-CHOP/R-DHAP was 70.5% compared with 62.0% for patients treated with R-CHOP, regardless of transplant status. R-CHOP/R-DHAP had more hospital admissions for fever, infection, neutropenia, and renal toxicity. TI patients received BR (n = 303) or historical regimens (n = 189). BR was associated with lower mortality. After adjustment, maintenance rituximab was associated with significantly lower mortality (hazard ratio, 0.33; 95% confidence interval, 0.24-0.44). More patients treated with BR had hospital admissions for febrile neutropenia. In this large population-based study, R-CHOP/R-DHAP before ASCT showed a trend toward improved 5-year OS. BR did not result in superior OS after adjustment, suggesting other regimens followed by rituximab maintenance may be reasonable.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.